Edwards Lifesciences Stock News

Avantax Advisory Services Inc. cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 9.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,233 shares of the medical research companys stock after selling 672 shares during the period. Avantax Advisory Services Inc.s holdings []

Edwards Lifesciences Co. (NYSE:EW) Equities research analysts at Oppenheimer dropped their Q1 2022 earnings per share estimates for shares of Edwards Lifesciences in a research note issued on Thursday, December 9th. Oppenheimer analyst S. Kalia now anticipates that the medical research company will earn $0.51 per share for the quarter, down from their previous []

Edwards Lifesciences Co. - Research analysts at SVB Leerink upped their Q1 2022 EPS estimates for shares of Edwards Lifesciences in a report issued on Wednesday, December 8th

Edwards Lifesciences Co. (NYSE:EW) Research analysts at SVB Leerink upped their Q1 2022 EPS estimates for shares of Edwards Lifesciences in a report issued on Wednesday, December 8th. SVB Leerink analyst D. Antalffy now forecasts that the medical research company will post earnings of $0.59 per share for the quarter, up from their previous [] The post Edwards Lifesciences Co. to Post Q1 2022 Earnings of $0.59 Per Share, SVB Leerink Forecasts (NYSE:EW) appeared first on ETF Daily News .

OLD National Bancorp IN cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 3.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 204,256 shares of the medical research companys stock after selling 8,234 shares during the quarter. Edwards Lifesciences makes up about 0.9% of OLD National Bancorp INs investment portfolio, making the []

New York State Teachers Retirement System trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 724,995 shares of the medical research companys stock after selling 14,466 shares during the quarter. New York State Teachers Retirement []

Edwards Lifesciences Co. (NYSE:EW) Stock analysts at SVB Leerink lifted their Q1 2022 EPS estimates for Edwards Lifesciences in a note issued to investors on Wednesday, December 8th. SVB Leerink analyst D. Antalffy now forecasts that the medical research company will earn $0.59 per share for the quarter, up from their prior estimate of []

Kestra Private Wealth Services LLC raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,144 shares of the medical research companys stock after acquiring an additional 499 shares during the quarter. Kestra []

Edwards Lifesciences (NYSE:EW) had its price target raised by Piper Sandler from $123.00 to $133.00 in a research report sent to investors on Wednesday, The Fly reports. Piper Sandler currently has an overweight rating on the medical research companys stock. Several other research firms have also commented on EW. Wells Fargo & Company upgraded shares []

Edwards Lifesciences (NYSE:EW) had its price target upped by Piper Sandler from $123.00 to $133.00 in a research report sent to investors on Wednesday morning, The Fly reports. The firm currently has an overweight rating on the medical research companys stock. A number of other research analysts have also commented on the company. Wells Fargo []

Edwards Lifesciences CEO Michael Mussallem appeared on Wednesday's episode of "Mad Money," after the medical technology firm held its annual investor conference.

Edwards Lifesciences (NYSE:EW) updated its FY 2022 earnings guidance on Wednesday. The company provided earnings per share guidance of $2.500-$2.650 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.580. The company issued revenue guidance of $5.50 billion-$6 billion, compared to the consensus revenue estimate of $5.85 billion.Edwards Lifesciences also []

Edwards Lifesciences (NYSE:EW) updated its FY22 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $2.50-2.65 for the period, compared to the Thomson Reuters consensus estimate of $2.57. The company issued revenue guidance of $5.5 $6.0 billion, compared to the consensus revenue estimate of $5.85 billion.Edwards Lifesciences also updated its []

Murphy Capital Management Inc. lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,502 shares of the medical research companys stock after acquiring an additional 227 shares during the quarter. []

The Brain Monitoring Devices is an electroencephalogram is a test that detects electrical movement in your brain using small, metal discs devoted to your scalp. Your brain cells connect via electrical impulses and are vigorous all the time, even when